🇺🇸 Sm-153 in United States
34 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 34
Most-reported reactions
- Thrombocytopenia — 6 reports (17.65%)
- Metastases To Lung — 4 reports (11.76%)
- Abdominal Hernia — 3 reports (8.82%)
- Asthenia — 3 reports (8.82%)
- Bone Pain — 3 reports (8.82%)
- Breast Cancer Metastatic — 3 reports (8.82%)
- Cancer Pain — 3 reports (8.82%)
- Fatigue — 3 reports (8.82%)
- Ileus — 3 reports (8.82%)
- Metastases To Central Nervous System — 3 reports (8.82%)
Other Oncology approved in United States
Frequently asked questions
Is Sm-153 approved in United States?
Sm-153 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Sm-153 in United States?
Radiation Therapy Oncology Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.